<DOC>
	<DOCNO>NCT01478269</DOCNO>
	<brief_summary>This study retrospective analysis homogeneous population patient aggressive B-cell lymphoma treat upfront R-CHOP R-CHOP like regimen reassess prognostic factor hopefully identify accurate prognostic subgroup clinical therapeutical relevance .</brief_summary>
	<brief_title>Prognosis Of Patients With Aggressive B-Cell Lymphoma , Treated With Rituximab+Anthracycline Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histologically confirm newly diagnose aggressive Bcell lymphoma accord current World Health Organisation Classification , 2001 2007 . 2 . Any stage disease . 3 . Treatment RCHOP RCHOP like regimen ( +/ transplant ) . 4 . Age least 18 year . 5 . Availability tissue biopsy diagnosis possible centralized revision . 6 . Availability data clinical involvement , laboratory , treatment follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Aggressive B-cell lymphoma</keyword>
	<keyword>R-CHOP</keyword>
</DOC>